US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
株式
アメリカ
USOTC
Tsuruha Holdings Inc (PK) (TSUSF) 銘柄情報

Tsuruha Holdings Inc (PK) (TSUSF)

17.25

0.00

( 0.00% )

更新日時： 20:32:06

Tsuruha Holdings Inc (PK) (TSUSF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

17.25

( - )

買値

11.70

売値

14.06

出来高

-

0.00 日の範囲 0.00

11.00 52 週間の範囲 55.00

時価総額

前日終値

17.25

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 2,500,257

発行済株式数

453,115,986

配当利回り

49.7

PER

13.79

1 株当たり利益 (EPS)

144.08

歳入

1.45T

純利益

42.67B

Tsuruha Holdings Inc., together with its subsidiaries, operates drugstores in Japan. The company sells pharmaceutical, cosmetic, miscellaneous goods and food products. It is also involved in group support business; provision of Tsuruha drug care services, wellness care center, and lady care shop act... Tsuruha Holdings Inc., together with its subsidiaries, operates drugstores in Japan. The company sells pharmaceutical, cosmetic, miscellaneous goods and food products. It is also involved in group support business; provision of Tsuruha drug care services, wellness care center, and lady care shop active; and overseas business. The company was founded in 1929 and is headquartered in Sapporo, Japan. 詳細を表示

セクター

Healthcare

業界

Healthcare Providers & Services

ウェブサイト

www.tsuruha-hd.co.jp

本社

Sapporo, Japan

設立

2026

Tsuruha Holdings Inc (PK) is listed in the Healthcare sector of the その他OTC with ticker TSUSF. The last closing price for Tsuruha (PK) was US$17.25. Over the last year, Tsuruha (PK) shares have traded in a share price range of US$ 11.00 to US$ 55.00.

Tsuruha (PK) currently has 453,115,986 shares in issue. The market capitalisation of Tsuruha (PK) is US$7.82 billion. Tsuruha (PK) has a price to earnings ratio (PE ratio) of 13.79.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	17.25	17.25	17.25	0	0	CS
26	0	0	17.25	17.25	17.25	0	0	CS
52	-37.75	-68.6363636364	55	55	11	6	17.25	CS
156	-57.05	-76.7833109017	74.3	91.8	11	739	63.60767887	CS
260	-109.29	-86.3679468943	126.54	131	11	823	82.82034039	CS

TSUSF - Frequently Asked Questions (FAQ)

What is the current Tsuruha Holdings Inc (PK) share price?

The current share price of Tsuruha Holdings Inc (PK) is US$ 17.25

How many Tsuruha Holdings Inc (PK) shares are in issue?

Tsuruha Holdings Inc (PK) has 453,115,986 shares in issue

What is the market cap of Tsuruha Holdings Inc (PK)?

The market capitalisation of Tsuruha Holdings Inc (PK) is USD 7.82B

What is the 1 year trading range for Tsuruha Holdings Inc (PK) share price?

Tsuruha Holdings Inc (PK) has traded in the range of US$ 11.00 to US$ 55.00 during the past year

What is the PE ratio of Tsuruha Holdings Inc (PK)?

The price to earnings ratio of Tsuruha Holdings Inc (PK) is 13.79

What is the cash to sales ratio of Tsuruha Holdings Inc (PK)?

The cash to sales ratio of Tsuruha Holdings Inc (PK) is 0.62

What is the registered address of Tsuruha Holdings Inc (PK)?

The registered address for Tsuruha Holdings Inc (PK) is 20-1-21, Kita 24 Johigashi, Sapporo, Hokkaido, 065-0024

What is the Tsuruha Holdings Inc (PK) website address?

The website address for Tsuruha Holdings Inc (PK) is www.tsuruha-hd.co.jp/

Which industry sector does Tsuruha Holdings Inc (PK) operate in?

Tsuruha Holdings Inc (PK) operates in the Healthcare Providers & Services sector

2times2

2times2 2分前

Summer months typically are not the season for OTC ticker spikes...I, as well, hope for a spike as twice this year already and given the tiny market cap NXGB could...but we know also that the CEO never addresses the reason and limits for the dilution which leave the taste that she will continue

doogdilinger

doogdilinger 3分前

Our burgeoning EVLI fire breathing dragon 🐉 hasn’t even begun its oncoming summer fun, but it’s coming real soon 🚀

BlazingStocks

BlazingStocks 3分前

🔥 This is exactly the type of strategic initiative investors look for.
A venture platform powered by proprietary AI, supported by acquisition expertise, and backed by an established growth strategy creates a differentiated approach to building long-term shareholder value as Nocera Hol

BEIJING BILL

BEIJING BILL 3分前

Big deal TD.. the president has many charges against him and judgements as well . The last time I look . Mr. Trump is doing quite well.
So yu have no point in what u saying.

maxluke1

maxluke1 3分前

INTU - thanks for excellent reply.

I guess here's some observations from my own work (engineering/science field) that I think are relevant. In my work, yes, the AI can be wrong, but it's not about the AI being only right 90% of the time and that being an issue. It's about the fact tha

europa7

europa7 3分前

Stellar (XLM)'s Quantum Plan: Preparing for Post-Quantum Threats
Jun 09, 2026
https://blockchain.news/news/stellar-quantum-preparedness-plan

1plus1

I'M TRYING TO READ ALL FILINGS FROM YOU SEND US A LINKS FROM 2024 AND NOW 2026 , BY NOW PPS SHOULD BE AROUND .10 CENTS ... DO YOU AGREE ? OR ALL THE NEWS IS PLAIN FLUFF ?

MarkMonkey

MarkMonkey 3分前

Myth

Over Under Sideways Down · The Yardbirds ( Jeff Beck )

https://www.youtube.com/watch?v=1CYaCoQlGuA

doogdilinger

doogdilinger 4分前

Watch and learn like always! Nobody gets meetings with major airlines if they’ve got nothing to offer of consequence 🔥

satter

Didn’t the bank case say Natario was a director at Hiru?

NO. Neither the bank nor any of the filings ever claimed that. In fact, Hiru's own defense counsel argued in their court submissions that the actions were carried out by "unrelated parties."

Your attempt at creati

BEIJING BILL

BEIJING BILL 5分前

Yu Wong TD!!! Again yu not know what is going on with revere securities... If it's to unload stock ... Alpine takes care of that.
There is much more to revere than yu think I bet

ExtremelyBullishZig

ExtremelyBullishZig 5分前

I am thinking of submitting my resume to Anavex for the CEO position...how does this opening to my cover letter sound?

"I am confident that my lack of experience in biotech makes me more qualified than your previous CEO"

double_m

double_m 5分前

A few things to look at before referencing the Space-x IPO with Delfin's situation:

1. Space-x has had pre-IPO revenue ($14B in '23 and almost $20B last year). Anything Delfin brought in is leveraged towards future operations.
2. Space-x has employee stock options - incentive

LCLiving

LCLiving 5分前

I know... There is always 1 somewhere. Too emotional to be playing down here in the dark basement.

Laster

Oops. I was wrong about this play. Sorry.
No support. Lots of selling into bids.
Stock has no strength when the Q's are weak.

Investor082

Investor082 5分前

BS again. Study Revolution Medicine for how successful pre-venue biotechs behave. NWBO is a dilution scam where excuses, victim mindset, and blame games are a norm.

I feel sorry for anyone that invested 12-13 years ago and started following your BS commentary. They will never come clo

Monksdream

Monksdream 5分前

HKIT, there it goes

AJH92

$PSRU Multiple lines of business development coming to fruition in 2026 and future years.

2025 Annual Net Profit of $1.5M+ increasing with 2026 Q1 Net Profit of $448.5K.

No need for a reverse split as no need for dilution for over 8 months.

Overview here:

Laster

If the story is so great, then who would be swelling at $0.0025? Ask yourself that question.
I have answered it over and over here.
Buyer beware. JMO.

Jack_Bolander

Jack_Bolander 6分前

rick - Big Deal. Do they sell Beaver Nuggets ? Deer Corn ? Live Bait ?

Buckees Rules.

doogdilinger

doogdilinger 7分前

Exactamundo NewBreed, and they’ve laid it all out for us as to what’s coming next 🚀

ExtremelyBullishZig

ExtremelyBullishZig 7分前

Judging from all the "proof" and length of your post, you haven't made much here. Good try though.
But you and your alter ego George sure know how to manipulate stocks together...

WHITTENHALLJR

WHITTENHALLJR 7分前

Any life here in the otc for THIS COMPANY?

Whalatane

Whalatane 7分前

By the way ...
Unicycive Therapeutics (UNCY) is legally permitted to negotiate a standalone commercialization deal with DaVita, unless they choose to sign a strictly "exclusive, all-inclusive" U.S. license with CSL Vifor.

In the renal and dialysis pharmaceutical market, biotech

BetaShares Capital

Invex Therapeutics

International bond 0% 15...

Boosh Plant Based Brands (EM)

Boost Euro STOXX Banks 3...

Baristas Coffee (EM)

Amundi Global Government...

iShares Lithium & Batter...

I GLOBAL SOVEREIGN UCITS...

Alfa Financial Software

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。